ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,789,121 | +20.7% | 3,108,883 | +38.7% | 0.37% | +35.8% |
| Q2 2023 | $53,673,507 | +65.3% | 2,241,065 | +29.9% | 0.27% | +57.5% |
| Q1 2023 | $32,476,282 | +39.5% | 1,725,626 | +18.0% | 0.17% | +38.1% |
| Q4 2022 | $23,285,452 | -7.4% | 1,462,654 | -4.8% | 0.13% | -0.8% |
| Q3 2022 | $25,143,000 | +10.0% | 1,536,834 | -5.2% | 0.13% | +18.7% |
| Q2 2022 | $22,851,000 | -45.0% | 1,621,768 | -5.5% | 0.11% | -19.5% |
| Q1 2022 | $41,560,000 | -3.2% | 1,715,937 | -6.7% | 0.13% | +23.1% |
| Q4 2021 | $42,943,000 | +19.0% | 1,839,853 | -15.3% | 0.11% | +25.6% |
| Q3 2021 | $36,093,000 | -47.2% | 2,172,958 | -22.5% | 0.09% | -46.6% |
| Q2 2021 | $68,374,000 | -4.9% | 2,803,367 | +0.6% | 0.16% | -14.4% |
| Q1 2021 | $71,886,000 | -43.8% | 2,786,262 | +16.5% | 0.19% | -43.5% |
| Q4 2020 | $127,868,000 | +49.2% | 2,391,842 | +15.1% | 0.33% | +33.7% |
| Q3 2020 | $85,724,000 | +45.8% | 2,078,148 | +71.3% | 0.25% | +28.4% |
| Q2 2020 | $58,809,000 | -38.3% | 1,213,308 | -46.2% | 0.19% | -7.6% |
| Q1 2020 | $95,296,000 | +105.2% | 2,255,544 | +107.8% | 0.21% | +22.8% |
| Q4 2019 | $46,446,000 | +28.1% | 1,085,683 | +7.8% | 0.17% | +20.4% |
| Q3 2019 | $36,250,000 | +71.1% | 1,007,214 | +27.1% | 0.14% | +75.3% |
| Q2 2019 | $21,187,000 | -28.1% | 792,616 | -27.8% | 0.08% | -30.8% |
| Q1 2019 | $29,481,000 | +71.7% | 1,097,991 | +3.4% | 0.12% | +48.1% |
| Q4 2018 | $17,168,000 | -25.8% | 1,061,696 | -4.8% | 0.08% | -9.2% |
| Q3 2018 | $23,150,000 | +65.3% | 1,115,135 | +21.6% | 0.09% | +47.5% |
| Q2 2018 | $14,001,000 | -54.4% | 916,886 | -33.0% | 0.06% | -58.7% |
| Q1 2018 | $30,732,000 | -52.9% | 1,367,683 | -36.9% | 0.14% | -51.4% |
| Q4 2017 | $65,219,000 | -13.5% | 2,166,029 | +8.3% | 0.29% | -16.5% |
| Q3 2017 | $75,356,000 | +18.4% | 2,000,434 | -12.3% | 0.35% | +15.8% |
| Q2 2017 | $63,642,000 | -15.1% | 2,281,895 | +4.7% | 0.30% | -18.5% |
| Q1 2017 | $74,957,000 | +31.9% | 2,180,249 | +10.6% | 0.37% | +20.7% |
| Q4 2016 | $56,827,000 | -18.0% | 1,970,419 | -9.5% | 0.31% | -13.2% |
| Q3 2016 | $69,262,000 | -10.5% | 2,177,381 | -8.7% | 0.36% | -13.0% |
| Q2 2016 | $77,422,000 | +70.9% | 2,385,163 | +47.2% | 0.41% | +78.6% |
| Q1 2016 | $45,295,000 | +227.7% | 1,620,014 | +317.8% | 0.23% | +241.8% |
| Q4 2015 | $13,824,000 | -52.4% | 387,754 | -55.8% | 0.07% | -57.6% |
| Q3 2015 | $29,020,000 | +1891.8% | 877,529 | +2421.6% | 0.16% | +2157.1% |
| Q2 2015 | $1,457,000 | -28.3% | 34,800 | -44.2% | 0.01% | -22.2% |
| Q1 2015 | $2,031,000 | -85.8% | 62,325 | -86.2% | 0.01% | -87.0% |
| Q4 2014 | $14,289,000 | +24.6% | 450,045 | -2.9% | 0.07% | +23.2% |
| Q3 2014 | $11,471,000 | -2.7% | 463,284 | -11.2% | 0.06% | -3.4% |
| Q2 2014 | $11,785,000 | -25.4% | 521,710 | -19.7% | 0.06% | -25.6% |
| Q1 2014 | $15,799,000 | -38.1% | 649,354 | -36.4% | 0.08% | -40.0% |
| Q4 2013 | $25,525,000 | +44.9% | 1,021,413 | +59.3% | 0.13% | +32.7% |
| Q3 2013 | $17,615,000 | +74.9% | 641,263 | +15.6% | 0.10% | +63.3% |
| Q2 2013 | $10,071,000 | – | 554,849 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |